Can’t find what you’re looking for? Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Order Online! Now! Get your $50 coupon for online order. 
Order Online! Now! Get your $50 coupon for online order.
Get your basement membrane extract free sample to test now! Get your basement membrane extract free sample to test now!
Time Limited Offer: Welcome Gift for New Customers ! Shipping Price Reduction for EU Regions
Hot Products: Multi-pass transmembrane proteins
GMP grade products
| Cat. No. | Product Description | Size&Price | Compare |
| EBS-002 | ELISA Buffer Set (Phosphate system, 96T) |
|
Hot Products: Multi-pass transmembrane proteins GMP grade products
| Cat. No. | Product Description | Size&Price | Compare |
| MB-01 | Magnetic Stand for 4 Tubes (15mL, 50mL) |
|
|
| MB-02 | Magnetic Stand for 12 Tubes (1.5mL, 2mL) |
|
Hot Products: Multi-pass transmembrane proteins GMP grade products
| Cat. No. | Product Description | Size&Price | Compare |
| FCM-C03M | Magnetic Capture Plate |
|
|
| FCM-B01M | 96-Well Filter Plate |
|
Hot Products: Multi-pass transmembrane proteins GMP grade products
| Cat. No. | Product Description | Size&Price | Compare |
| CHEK-SP01 | HEK293 Cell Line |
|
Hot Products: Multi-pass transmembrane proteins GMP grade products
| Cat. No. | Product Description | Size&Price | Compare |
| DB-02 | Dilution Buffer (Strengthen Blocking) |
|
|
| DC-11 | 200x DDM CHS buffer |
|
Hot Products: Multi-pass transmembrane proteins GMP grade products
| Target | Project item | Indications | Research phase | Cooperation demands |
| - | BHE202220 | NASH | IND, IP has been granted in the US, CN, etc | License-out or co-development the global right |
| - | BJM202301 | Hematological malignancy and Solid tumors | IND-approved | License-out or co-development |
| - | BNO202203 | IBD, expanded indication COVID-19 | IND ready | License-out or co-development |
| - | BDB202301 | Glioblastoma | Ready to start phase 1 (improved variant of Temodex®) | license-out or co-development Globally except in CIA |
| - | BDA202205 | bacterial infections caused by specific microbial sensitive strains, such as complex or non-complex skin and skin soft tissue infections, community/hospital acquired pneumonia, vancomycin-resistant enterococcal infections, other bone and joint infections, | IND | License-out or co-development the global right |
| - | NSS21001 | Cancer Cachexia | Preclinical | License-out or co-development the global right |
| - | BHE202218 | CKD and Renal anemia | Phase 1 | License-out or co-development of the global right (except for China) |
| - | BHE202219 | Idiopathic pulmonary fibrosis (IPF) and solid tumor, (FDA ODD） | Phase 1 | License-out or co-development |
| - | BHE202217 | Migraine | Phase 1 | License-out or co-development |
| - | BHE202207 | HBV | Phase 3 China, Phase 2, US | License-out or co-development |
| - | BHE202211 | Hematologic malignancies | Phase I, China; the patent has been granted in the US | License-out and co-development |
| - | BHE202216 | HBV | Phase 1 | License-out or co-development |
| - | BHE202202 | NSCLC, Medullary thyroid cancer, Thyroid cancer | Phase 1 | License-out or co-development |
| - | BHE202206 | Depression | Phase II/ III | License-out or co-development |
| - | BHE202213 | Pulmonary arterial hypertension (PAH), Chronic thromboembolic pulmonary hypertension (CTEPH), Heart failure with reduced ejection fraction (HFrEF), Chronic kidney disease (CKD) | Phase 1, IP has been granted in US, AU, CN | License-out or co-development |
| - | BHE202203 | Hyperuricemia (HUA) | Phase 1 is ongoing in China | License-out or co-development |
| - | BHE202205 | NASH | Phase I is finished in AU/Phase II is ongoing in CN | License-out or co-development |
| - | BHE202208 | Diabetes | Phase III | Out licensing global right |
| - | BHE202214 | Diabetic kidney disease | Phase I is ongoing in China | Out licensing global right |
This web search service is supported by Google Inc.
A-Z
